Carole Garcia

Direttore/Membro del Consiglio presso ACTIA GROUP

54 anni

Commercial Services

Producer Manufacturing

Consumer Services

Profilo

Ms. Carole Garcia is an Independent Director at Actia Group, a President at Graine de Pastel SAS, a Chairman at Financière Graine de Pastel SC, a Manager at Sci Clement Laffont, a Member at Academie Des Arts Et Des Sciences Du Pastel and a Member-New Economy & Growth Commission at Chambre de commerce et d'Industrie de Toulouse.
She is on the Board of Directors at Actia Group.
Ms. Garcia was previously employed as a Head-Marketing by Pierre Fabre Pharmaceuticals, Inc. and a Member by Le Cercle d’Oc.
She received her graduate degree from Université Paris Dauphine-PSL.

Posizioni attive di Carole Garcia

Società	Posizione	Inizio
ACTIA GROUP	Direttore/Membro del Consiglio	28/05/2014
Graine de Pastel SAS Graine de Pastel SAS Household/Personal CareConsumer Non-Durables Manufactures and distributes cosmetics and other beauty products	Fondatore	01/01/2002
Financière Graine de Pastel SC Financière Graine de Pastel SC MiscellaneousMiscellaneous Operates as a holding company	Presidente	-
Sci Clement Laffont Sci Clement Laffont Real Estate DevelopmentFinance Leases real estate properties	Corporate Officer/Principal	-
Academie Des Arts Et Des Sciences Du Pastel Academie Des Arts Et Des Sciences Du Pastel Miscellaneous Commercial ServicesCommercial Services Operates arts and sciences academy as well as other voluntary membership organization	Corporate Officer/Principal	-
Chambre de commerce et d'Industrie de Toulouse Chambre de commerce et d'Industrie de Toulouse Miscellaneous Commercial ServicesCommercial Services Operates as employers and consular organization	Corporate Officer/Principal	-

Tutte le posizioni attive di Carole Garcia

Precedenti posizioni note di Carole Garcia

Società	Posizione	Fine
Le Cercle d’Oc	Corporate Officer/Principal	01/01/2021
Pierre Fabre Pharmaceuticals, Inc. Pierre Fabre Pharmaceuticals, Inc. Medical DistributorsDistribution Services Part of Pierre Fabre Participations SAS, Pierre Fabre Pharmaceuticals, Inc. is a company that offers Hemangeol, an FDA-approved oral propranolol hydrochloride solution formulated to treat proliferating infantile hemangioma, a common benign vascular tumor in infants that may require systemic therapy to prevent complications affecting vision, breathing, or feeding. The company is based in Parsippany, NJ. The product is designed for infants, featuring a strawberry-vanilla flavor and is free of alcohol, sugar, and parabens, and is supplied with a child-resistant dosing syringe. Treatment typically begins between 5 weeks and 5 months of age and continues for about six months, with weight-based dosing administered twice daily during or after feeding. Safety information includes contraindications such as premature infants under five weeks corrected age, low body weight, asthma, certain cardiac conditions, and propranolol allergy, with potential side effects including hypoglycemia, bradycardia, hypotension, bronchospasm, cardiac failure, increased stroke risk in certain conditions, and hypersensitivity reactions. Common side effects are sleep disturbances, respiratory infections, diarrhea, and vomiting. The product includes dosing charts, calculators, and caregiver support tools to assist with treatment adherence and monitoring. Pierre Fabre Pharmaceuticals provides resources for healthcare professionals, pharmacists, and caregivers, including prescribing information, safety guidelines, educational materials, and patient assistance programs, and collaborates with patient advocacy groups to enhance education and support for families managing infantile hemangiomas.	Vendite & Marketing	01/01/2001

Vedi nel dettaglio l'esperienza di Carole Garcia

Formazione di Carole Garcia

Esperienze
Posizioni ricoperte

Attive

Inattive

Società nel listino

Aziende private

Vedi nel dettaglio l'esperienza di Carole Garcia

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	9
Actia Group Actia Group Auto Parts: OEMProducer Manufacturing Manufactures and distributes OEM and aftermarket parts, amplifiers, transmit & receive subassemblies	Producer Manufacturing
Université Paris Dauphine-PSL Université Paris Dauphine-PSL Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Le Cercle d’Oc
Chambre de commerce et d'Industrie de Toulouse Chambre de commerce et d'Industrie de Toulouse Miscellaneous Commercial ServicesCommercial Services Operates as employers and consular organization	Commercial Services
Financière Graine de Pastel SC Financière Graine de Pastel SC MiscellaneousMiscellaneous Operates as a holding company	Miscellaneous
Graine de Pastel SAS Graine de Pastel SAS Household/Personal CareConsumer Non-Durables Manufactures and distributes cosmetics and other beauty products	Consumer Non-Durables
Sci Clement Laffont Sci Clement Laffont Real Estate DevelopmentFinance Leases real estate properties	Finance
Academie Des Arts Et Des Sciences Du Pastel Academie Des Arts Et Des Sciences Du Pastel Miscellaneous Commercial ServicesCommercial Services Operates arts and sciences academy as well as other voluntary membership organization	Commercial Services
Pierre Fabre Pharmaceuticals, Inc. Pierre Fabre Pharmaceuticals, Inc. Medical DistributorsDistribution Services Part of Pierre Fabre Participations SAS, Pierre Fabre Pharmaceuticals, Inc. is a company that offers Hemangeol, an FDA-approved oral propranolol hydrochloride solution formulated to treat proliferating infantile hemangioma, a common benign vascular tumor in infants that may require systemic therapy to prevent complications affecting vision, breathing, or feeding. The company is based in Parsippany, NJ. The product is designed for infants, featuring a strawberry-vanilla flavor and is free of alcohol, sugar, and parabens, and is supplied with a child-resistant dosing syringe. Treatment typically begins between 5 weeks and 5 months of age and continues for about six months, with weight-based dosing administered twice daily during or after feeding. Safety information includes contraindications such as premature infants under five weeks corrected age, low body weight, asthma, certain cardiac conditions, and propranolol allergy, with potential side effects including hypoglycemia, bradycardia, hypotension, bronchospasm, cardiac failure, increased stroke risk in certain conditions, and hypersensitivity reactions. Common side effects are sleep disturbances, respiratory infections, diarrhea, and vomiting. The product includes dosing charts, calculators, and caregiver support tools to assist with treatment adherence and monitoring. Pierre Fabre Pharmaceuticals provides resources for healthcare professionals, pharmacists, and caregivers, including prescribing information, safety guidelines, educational materials, and patient assistance programs, and collaborates with patient advocacy groups to enhance education and support for families managing infantile hemangiomas.	Distribution Services